Skip to main content
Lir Life Sciences Corp. logo

Lir Life Sciences Corp. — Investor Relations & Filings

Ticker · SKNY LEI · 894500GZQCXFABJI4496 CSE Manufacturing
Open in API
Filings indexed 141 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country CA Canada
Listing CSE SKNY

About Lir Life Sciences Corp.

https://lirlife.com

Lir Life Sciences Corp. is a biopharmaceutical company specializing in the development of next-generation therapies for obesity and metabolic disorders. The company's core focus is advancing treatment accessibility through innovative drug-delivery approaches, specifically developing transdermal and alternative GLP-1 solutions. These therapies are designed to be scalable, affordable, and accessible globally, aiming to reduce reliance on traditional injections. Lir Life Sciences targets regions with rising obesity rates and limited access to existing GLP-1 treatments, addressing a significant unmet need in the rapidly growing global market.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory form for the 'Certification of Interim Filings'. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference an interim report, should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements or substantive financial data. Q3 2025
2025-12-29 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is explicitly titled 'MANAGEMENT DISCUSSION AND ANALYSIS' (MD&A) for the six months ended October 31, 2025. It provides a detailed narrative explanation of the company's financial results, operational changes (including an RTO and name change), and business outlook. This aligns perfectly with the definition of a Management Report (MDA).
2025-12-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for the three and six months ended October 31, 2025 and 2024. It includes comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Shareholders' Equity, and Statement of Cash Flows) along with detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. H1 2026
2025-12-29 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a news release from LIR Life Sciences covering multiple corporate events: the appointment of a new scientific advisor, the engagement of a market maker (VLP), and the grant of Restricted Share Units (RSUs) to directors and officers. Since the document contains multiple announcements that do not fit into a single specific category like 'Director's Dealing' or 'Management Information' exclusively, and it is a general regulatory news release, it is best classified under the fallback category for regulatory announcements.
2025-12-19 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing the conditional approval from the Canadian Securities Exchange for the company’s fundamental change via acquisition of Lir Life Sciences, including detailed terms of the share purchase agreement, share consolidation and listing conditions. It is not a financial report, earnings release, board change notice or dividend announcement, but rather an M&A transaction announcement. Therefore, it fits the M&A Activity category.
2025-11-05 English
Cover letter.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a formal notification to securities regulators under Policy 9 regarding a share consolidation (1-for-1.5) and corporate name change. It announces a capital structure change (new share ratio, trading symbol, CUSIP/ISIN) rather than providing financial results or other reports. This matches the “Share Issue/Capital Change” category (Code SHA).
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.